Thomas Grombacher is the Associate Scientific Director of Bioinformatics at Mercks healthcare business, focusing on computational drug discovery and oncology. Holding a PhD from the Karlsruhe Institute of Technology, his long career at Merck is marked by co-authoring numerous publications on DNA damage response and pharmacogenomics.
He is a key contributor to research on novel cancer therapies, co-authoring studies on inhibitors that target critical DNA repair pathways in tumor cells.
Thomas Grombacher
Associate Scientific Director Bioinformatics at Healthcare Business of Merck
Germany
Overview
Topics They Care About
Oncology Drug Discovery
He has co-authored multiple recent studies on novel inhibitors for cancer therapy, particularly focusing on DNA Damage Response (DDR) pathways.
Computational Biology
His work involves bioinformatics and computational methods to analyze protein binding sites, predict druggability, and support the drug development process.
Pharmacogenomics
Co-authored a recent paper on using whole-exome sequencing for pharmacogenomics profiling, demonstrating an interest in personalized medicine approaches.
Media Appearances
Thomas has no verified media appearances
Work History
1-2016
Associate Scientific Director Bioinformatics at Healthcare Business of Merck
8-2010 - 12-2015
Group Leader Discovery Bioinformatics at Healthcare Business of Merck
3-2011
Principal Research Scientist Bioinformatics at Healthcare Business of Merck
3-2000
Research Scientist Bioinformatics (Postdoc) at Aventis
Education
1995 - 1998
PosDoc from Johannes Gutenberg University Mainz
1992 - 1995
PhD from Karlsruhe Institute of Technology (KIT)
More Information
Social Presence :
Prographics :
Exp : 15
Location : Germany
Job Level : Mid-senior
Designation : Associate Scientific Director Bioinformatics at Healthcare Business of Merck
